Table 2.

Summary of Presented Cases at Time of PCP diagnosis

	Patients	1	2	3	4	5	6	Median [IQR] or No. (%)
Demographics	Age, y	84	49	58	61	69	66	63.5 [58–69]
…	Sex	Female	Female	Male	Female	Male	Male	3/6 (50) female
…	Mortality at hospital dischargea	Living	Deceased	Living	Living	Living	Living	1/6 (16.7) deceased
COVID-19	Risk factors at PCP diagnosis	HTN, CAD, asthma, IgM deficiency	DM2, HTN, CAD, obese, S/P SOT (tacrolimus, corticosteroids, mycophenolate)	MM II, S/P ASCT long-term corticosteroids	CKD, DLBL IV	Obese, methotrexate for RA	HTN	5/6 (83.3) had PCP risk factors before COVID-19
…	Treatment	Remdesivir, dexamethasone	Remdesivir, dexamethasone	Remdesivir, dexamethasone, bamlanivimab-etesevimab	Dexamethasone, baricitinib, casirivimab- imdevimab	Remdesivir, CP, dexamethasone	Remdesivir, dexamethasone	…
…	Prednisone-equivalent steroid administration,b mg	400	660 + 5 daily for SOT	240 + 130 weekly for MM/ASCT	1310	400	930	530 [400–930]
Pneumocystis	Status	Probable	Probable	Probable	Probable	Probable	Probable	6/6 (100)
…	Diagnosis method	BAL PCR, β−D-Glucan	β−D-Glucan, LDH, clinical picture	BAL PCR, β−D-Glucan	BAL PCR, β−D-Glucan	Sputum PCR, clinical picture	BAL PCR, β−D-Glucan	…
…	Risk factors at PCP diagnosis	Corticosteroids	Immune compromised, corticosteroids	Immune compromised, corticosteroids,	Immune compromised, corticosteroids	Immune compromised, corticosteroids	Corticosteroids	6/6 (100) corticosteroids
…	Treatment	TMP-SMX, then atovaquone	TMP-SMX	TMP-SMX, then atovaquone, prednisone	TMP-SMX, prednisone	TMP-SMX, then atovaquone	TMP-SMX, then atovaquone, prednisone	…
…	Time of PCP diagnosis, d from COVID-19 diagnosis	39	19	58	199	16	43	41 [19–58]
Laboratory findings	β−D-Glucan [<80], pg/mL	191	137	>500	>500	31	292	241.5 [137–>500]
…	LDH [91–180], units/L	303	536	204	320	398	428	359 [303–428]
…	ALC [1.0–4.8], K/mm3	…	0.54	1.56	0.61	0.64	0.97	0.64 [0.58–1.27]
…	CD4 count [>200], cells/mm3	34	…	243	382	56	…	200 [56–382]
…	Lowest PaO2,  mmHg	78	45	72	52	58	45	55 [45–72]
Imagining findings	CT chest	Bilateral infiltrates and diffuse ground glass opacitiesc	Bilateral nodules and diffuse ground glass opacities	Diffuse ground glass opacities with new, focal nodular opacities	Diffuse ground glass opacities	New peripheral infiltrates	Diffuse ground glass opacities and prominent mediastinal lymph nodes	…
Hospital stay	ICU stay	Yes	Yes	No	Yes	Yes	No	4/6 (66.7) ICU admission
…	ICU days	10	13	N/A	27	7	N/A	10 [4.5–20]
…	Mechanical ventilation	Yes	Yes	No	Yes	No	No	3/6 (50) MV

Roman numerals indicate stage of malignancy.

Abbreviations: ALC, absolute lymphocyte count; ASCT, autologous hematopoietic stem cell transplant; BAL, bronchoalveolar lavage; CAD, coronary artery disease; CKD, chronic kidney disease; CP, convalescent plasma; CT, computed tomography; DLBL, diffuse large B-cell lymphoma; DM2, type 2 diabetes mellitus; HM, hematogenic malignancy; HSCT, nonautologous hematopoietic stem cell transplant; HTN, hypertension; ICU, intensive care unit; IgM, immunoglobulin M; IQR, interquartile range; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; MM, multiple myeloma; PaO₂, partial pressure of arterial oxygen; PCP, Pneumocystis jirovecii pneumonia; PCR, polymerase chain reaction; RA, rheumatoid arthritis; S/P, status post; SOT, solid organ transplant; TMP-SMX, trimethoprim-sulfamethoxazole.

^aFrom hospitalization with PCP diagnosis.

^bPrednisone-equivalent dosing from time of COVID-19 diagnosis until PCP diagnosis. Daily or weekly administration of steroids for existing conditions is in addition to administration during hospital admittance for at least 6 months before hospitalization.

^cImaging findings at time of diagnosis only available on PA and lateral chest x-ray, but improving and comparable findings were found on CT chest at 1-month follow up.